BeiGene, Ltd. (NASDAQ:BGNE) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, August 8th. Analysts expect the company to announce earnings of ($1.24) per share for the quarter.

Shares of BeiGene, Ltd. (NASDAQ BGNE) opened at 72.31 on Monday. The firm’s 50-day moving average price is $59.96 and its 200-day moving average price is $43.43. The firm’s market capitalization is $2.87 billion. BeiGene, Ltd. has a one year low of $26.05 and a one year high of $79.25.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2017/08/07/beigene-ltd-nasdaqbgne-set-to-announce-earnings-on-tuesday.html.

In other BeiGene news, Director Xiaodong Wang sold 20,000 shares of the company’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $72.44, for a total value of $1,448,800.00. Following the sale, the director now owns 16,300 shares in the company, valued at $1,180,772. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Donald W. Glazer sold 10,810 shares of the company’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $72.15, for a total transaction of $779,941.50. Following the completion of the sale, the director now owns 7,206 shares in the company, valued at approximately $519,912.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 389,249 shares of company stock valued at $22,594,820. 24.20% of the stock is owned by insiders.

BGNE has been the subject of several recent analyst reports. Robert W. Baird upped their price objective on shares of BeiGene from $44.00 to $58.00 and gave the company an “outperform” rating in a research note on Thursday, July 6th. Maxim Group reaffirmed a “buy” rating and set a $52.00 price objective on shares of BeiGene in a research note on Thursday, May 11th. William Blair reaffirmed an “outperform” rating on shares of BeiGene in a research note on Thursday, June 1st. Morgan Stanley reaffirmed an “overweight” rating and set a $83.00 price objective on shares of BeiGene in a research note on Monday, July 10th. Finally, Zacks Investment Research raised shares of BeiGene from a “sell” rating to a “buy” rating and set a $79.00 price objective for the company in a research note on Tuesday, July 11th. Six investment analysts have rated the stock with a buy rating, BeiGene presently has an average rating of “Buy” and an average target price of $73.25.

About BeiGene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Earnings History for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.